Deze kunnen we een kwartaal opschuiven:
- Bekendmaking update intellectual property (IP) portfolio (patenten rondom Padua)
In de derde kwartaalrapportage staat: On January 4, 2020, a petition seeking Inter Partes Review of U.S. Patent No. 9,249,405 (the “’405 Patent”) was filed by Pfizer, Inc. The petition sought to invalidate claims 6 and 9-15 of the ‘405 Patent. On April 17, 2020, we filed our preliminary response to the petition, disclaiming claims 6 and 9-13 of the ‘405 patent and otherwise requesting the denial of the petition. On July 13, 2020, the United States Patent and Trademark Office issued its decision to institute the Inter Partes Review. On October 13, 2020, we filed a motion to amend the patent claims at issue in the proceeding. We expect that Pfizer will file a response to our motion in January 2021 pursuant to the current schedule for the proceeding.